Expanded extracolonic tumor spectrum in MUTYH-associated polyposis
- PMID: 19732775
- DOI: 10.1053/j.gastro.2009.08.052
Expanded extracolonic tumor spectrum in MUTYH-associated polyposis
Abstract
Background & aims: MUTYH-associated polyposis (MAP) is characterized by a lifetime risk of colorectal cancer of up to 100%. However, no systematic evaluation of extracolonic manifestations has been reported.
Methods: A large cohort of MAP patients was recruited from a European multicenter study. Data were collected on 276 cases from 181 unrelated families. Information on extracolonic tumor spectrum and incidence were evaluated to determine cumulative lifetime risk, which was compared with that of the general population to obtain standardized incidence ratios (SIRs).
Results: Duodenal polyposis occurred in 17% of cases; the relative risk (SIR) of duodenal cancer was 129 (95% confidence interval [CI]: 16-466), whereas the lifetime risk was 4%. The incidence of extraintestinal malignancies among cases was almost twice that of the general population (SIR: 1.9; 95% CI: 1.4-2.5), with a lifetime risk of 38%. We observed a significant increase in the incidence of ovarian, bladder, and skin cancers (SIR: 5.7, 7.2, and 2.8, respectively) and a trend of increased risk of breast cancer among cases. The median ages of onset of these 4 malignancies ranged from 51 to 61 years. In contrast to familial adenomatous polyposis, no desmoid tumors were observed, but sebaceous gland tumors, characteristic of the Muir-Torre variant of Lynch syndrome, occurred in 5 patients.
Conclusions: The relative risks for several extraintestinal malignancies increased in patients with MAP, but based on the spectrum of cancers (which overlaps with that of Lynch syndrome) and the relatively advanced age at onset, intensive surveillance measures other than frequent endoscopy are unlikely to be helpful to patients with MAP.
Comment in
-
MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story.Gastroenterology. 2009 Dec;137(6):1883-6. doi: 10.1053/j.gastro.2009.10.017. Epub 2009 Oct 29. Gastroenterology. 2009. PMID: 19879216 No abstract available.
Similar articles
-
MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story.Gastroenterology. 2009 Dec;137(6):1883-6. doi: 10.1053/j.gastro.2009.10.017. Epub 2009 Oct 29. Gastroenterology. 2009. PMID: 19879216 No abstract available.
-
Phenotype Correlations With Pathogenic DNA Variants in the MUTYH Gene: A Review of Over 2000 Cases.Hum Mutat. 2024 Sep 27;2024:8520275. doi: 10.1155/2024/8520275. eCollection 2024. Hum Mutat. 2024. PMID: 40225933 Free PMC article. Review.
-
Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin.Fam Cancer. 2008;7(2):187-9. doi: 10.1007/s10689-007-9161-9. Epub 2007 Sep 15. Fam Cancer. 2008. PMID: 17874208
-
Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations.Clin Genet. 2005 Nov;68(5):442-7. doi: 10.1111/j.1399-0004.2005.00519.x. Clin Genet. 2005. PMID: 16207212
-
MUTYH-associated polyposis.Best Pract Res Clin Gastroenterol. 2009;23(2):209-18. doi: 10.1016/j.bpg.2009.03.006. Best Pract Res Clin Gastroenterol. 2009. PMID: 19414147 Review.
Cited by
-
The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management.Appl Clin Genet. 2015 Apr 16;8:95-107. doi: 10.2147/TACG.S51484. eCollection 2015. Appl Clin Genet. 2015. PMID: 25931827 Free PMC article. Review.
-
Environmental and genetic risk factors for gastric cancer.J Surg Oncol. 2022 Jun;125(7):1096-1103. doi: 10.1002/jso.26869. J Surg Oncol. 2022. PMID: 35481919 Free PMC article. Review.
-
The missing heritability of familial colorectal cancer.Mutagenesis. 2020 Jul 11;35(3):221-231. doi: 10.1093/mutage/gez027. Mutagenesis. 2020. PMID: 31605533 Free PMC article. Review.
-
Papillary thyroid cancer in a patient with MUTYH-associated polyposis (MAP).Fam Cancer. 2010 Dec;9(4):595-7. doi: 10.1007/s10689-010-9366-1. Fam Cancer. 2010. PMID: 20625837
-
Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships.Front Genet. 2022 May 24;13:857120. doi: 10.3389/fgene.2022.857120. eCollection 2022. Front Genet. 2022. PMID: 35685436 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials